BioCentury reports that 23 base‑editor therapeutics have entered clinical development, with over half producing initial readouts that consistently show clinical activity. The tally spans in vivo and ex vivo programs targeting genetic diseases and oncology, and early data are refining the modalities’ safety and efficacy profiles. The accumulation of clinical experience is crystallizing where base editors may offer transformative one‑time precision cures and where technical or delivery hurdles remain.